These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8334424)

  • 1. Local cutaneous reaction induced by subcutaneous interleukin-2 and interferon alpha-2a immunotherapy following ABMT.
    Klapholz L; Ackerstein A; Goldenhersh MA; Vardy D; Nagler A
    Bone Marrow Transplant; 1993 Jun; 11(6):443-6. PubMed ID: 8334424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eosinophils activation in post-autologous bone marrow transplanted patients treated with subcutaneous interleukin-2 and interferon-alpha 2A immunotherapy.
    Fabian I; Kravtsov V; Elis A; Gurevitch O; Ackerstein A; Slavin S; Nagler A
    Leukemia; 1994 Aug; 8(8):1379-84. PubMed ID: 8057677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine-mediated immunotherapy following autologous bone marrow transplantation in lymphoma and evidence of interleukin-2-induced immunomodulation in allogeneic transplants.
    Slavin S; Nagler A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S59-67. PubMed ID: 9457396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral tuberculosis following autologous bone marrow transplantation for Hodgkin's disease with interleukin-2 and alpha-interferon immunotherapy.
    Toren A; Ackerstein A; Gazit D; Or R; Raveh D; Kupolovicz U; Engelhard D; Nagler A
    Bone Marrow Transplant; 1996 Jul; 18(1):209-10. PubMed ID: 8832017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation.
    Nagler A; Ackerstein A; Or R; Naparstek E; Slavin S
    Blood; 1997 Jun; 89(11):3951-9. PubMed ID: 9166832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation.
    Nagler A; Berger R; Ackerstein A; Czyz JA; Diez-Martin JL; Naparstek E; Or R; Gan S; Shimoni A; Slavin S
    J Immunother; 2010 Apr; 33(3):326-33. PubMed ID: 20445353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasive fungal infections in lymphoma patients receiving immunotherapy following autologous bone marrow transplantation (ABMT).
    Toren A; Or R; Ackerstein A; Nagler A
    Bone Marrow Transplant; 1997 Jul; 20(1):67-9. PubMed ID: 9232260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of autologous bone marrow transplantation followed by recombinant interleukin-2 in malignant lymphomas.
    Vey N; Blaise D; Tiberghien P; Attal M; Pico JL; Reiffers J; Harrousseau JL; Fiere D; Tabilio A; Gabus R; Brandely M; Maraninchi D
    Leuk Lymphoma; 1996 Mar; 21(1-2):107-14. PubMed ID: 8907277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with interleukin-2 (IL-2) and interferon (IFN(alpha 2b)) after autologous bone marrow or peripheral blood stem cell transplantation in onco-hematological malignancies with a high risk of relapse.
    Vivancos P; Grañena A; Sarrá J; Grañena A
    Bone Marrow Transplant; 1999 Jan; 23(2):169-72. PubMed ID: 10197803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
    Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
    Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon.
    Gryn J; Johnson E; Goldman N; Devereux L; Grana G; Hageboutros A; Fernandez E; Constantinou C; Harrer W; Viner E; Goldberg J
    Bone Marrow Transplant; 1997 Feb; 19(3):221-6. PubMed ID: 9028549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone morphology after bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma.
    Michelson JD; Gornet M; Codd T; Torres J; Lanighan K; Jones R
    Exp Hematol; 1993 Mar; 21(3):475-82. PubMed ID: 8440346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma.
    Kessinger A; Nademanee A; Forman SJ; Armitage JO
    Hematol Oncol Clin North Am; 1990 Jun; 4(3):577-87. PubMed ID: 1972701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interferon-alpha therapy in non-Hodgkin's lymphoma].
    Fridrik MA
    Wien Med Wochenschr; 1993; 143(16-17):429-34. PubMed ID: 8273367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged disease-free survival after ablative chemoradiotherapy and autologous bone marrow transplantation in adult malignant lymphoma.
    Da WM; Zhong JT; Liu Y; Huang YS; Bai H; Wu XX; Ou YX; Wang CB; Xu SF
    Chin Med J (Engl); 1993 Apr; 106(4):277-81. PubMed ID: 8325155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Autologous bone marrow transplantation for the treatment of malignant lymphoma in adults].
    Da WM; Zhong JT; Huang YS
    Zhonghua Nei Ke Za Zhi; 1992 Oct; 30(10):640-2, 660. PubMed ID: 1582346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
    Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
    Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interferon therapy in Hodgkin's disease].
    Heinz R; Möstl M
    Wien Med Wochenschr; 1993; 143(16-17):438-40. PubMed ID: 7505988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical studies for adoptive immunotherapy in bone marrow transplantation. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates.
    Ueda M; Joshi ID; Dan M; Uberti JP; Chou TH; Sensenbrenner LL; Lum LG
    Transplantation; 1993 Aug; 56(2):351-6. PubMed ID: 8356589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.